Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you take the progesterone-only pill (POP) and are considering Wegovy, the reassuring answer is that current NHS guidance does not flag reduced pill effectiveness as a concern with semaglutide in the way it does with tirzepatide. That said, there are nuances worth understanding before you start. Wegovy is a prescription-only medicine requiring clinical assessment; a prescriber decides whether it is appropriate for you personally, and contraception is one of the things they will ask about.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
You've probably seen warnings circulating about weight-loss injections and the pill, and you want to know whether your contraception is at risk. It's a reasonable thing to want pinned down before you commit to treatment. The short version: the concern about oral contraceptive absorption is documented more explicitly for tirzepatide (Mounjaro) than for semaglutide (Wegovy). NHS England's guidance on weight-management injections advises women using oral contraceptives to add a non-oral method for the first four weeks of tirzepatide treatment and after each dose increase, but makes no equivalent recommendation for semaglutide.
That distinction matters. The progesterone-only pill works differently from the combined pill and is already time-sensitive, most POPs require you to take them within a three-hour window each day. Adding a medicine that slows how quickly your stomach empties is worth discussing, and our page on Wegovy and the mini-pill goes into that specific combination in more detail. A prescriber reviewing your case through a service like Wegovy tablets will factor your specific contraception into that assessment.
Wegovy works partly by slowing gastric emptying: food and other substances spend longer in the stomach before moving into the small intestine, where most absorption happens. For some oral medicines, this delay can reduce peak blood levels or shift the timing of absorption. The question is whether the progesterone-only pill is affected enough for that to matter in practice.
Current evidence, as reflected in NHS England's guidance on weight-management injections, does not point to the same level of concern for semaglutide as it does for tirzepatide. The gastric-emptying effect of semaglutide is real but is generally considered less pronounced than that of tirzepatide, and to date no specific recommendation to use additional contraception alongside the POP has been issued for Wegovy users. That is not a green light to ignore contraception entirely, it is simply an accurate reading of the current guidance. If anything changes in your cycle, your pill-taking routine, or your circumstances, that conversation belongs with a clinician.
For a fuller picture of what the oral form of semaglutide involves, the Wegovy as a pill overview covers the licensed indication, dosing schedule and practical considerations in one place.
The MHRA's position applies to the GLP-1 class as a whole: use effective contraception during treatment, and allow a wash-out period before trying to conceive. Neither Wegovy nor the oral semaglutide tablet is recommended during pregnancy, breastfeeding, or when actively trying to conceive. For women who are not planning a pregnancy, continuing their current contraceptive method (including the progesterone-only pill) while on semaglutide is consistent with current guidance, provided no other clinical factors apply.
The NHS semaglutide medicines page lists contraception and pregnancy among the key topics to discuss with a pharmacist or doctor before starting treatment. It also notes that semaglutide may affect absorption of oral medicines taken at the same time. Taking your POP at a consistent time each day (and not alongside the Wegovy tablet if you move to oral semaglutide) is practical advice your prescriber can confirm for your specific regimen, and if you want to understand how that process works you can find out more about getting Wegovy as a pill online.
If you are curious about how the oral form compares to the injection in terms of practical daily use, the Wegovy pill form page sets out what distinguishes the two formats.
The most important thing is that your prescriber knows which contraception you use. This is not a formality. It shapes how they advise you, whether they recommend any additional precautions, and whether they flag anything specific to your health history. A good clinical review covers it as a matter of course.
At nume, every application is read by a GPhC-registered prescriber on the same day it arrives. That review includes your medicines, your contraception and any relevant medical history, not a checklist processed by software. If you want to explore whether oral semaglutide is suitable for you, the cost and access details are a useful starting point, and our FAQs answer the questions people most commonly arrive with. When you're ready, check your eligibility with a free consultation and a prescriber will take it from there.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.